BioCentury | Apr 2, 2021
Management Tracks

BeiGene unveils new CFO; plus Precigen, Alphamab, Flagship, Melinta, Immunome and more

...play Immunome Inc. (NASDAQ:IMNM) hired Dennis Giesing as chief development officer. Giesing was CSO at Taris...
BioCentury | Jul 16, 2020
Management Tracks

NextCure CMO Heller to resign; plus Vertex, Turning Point, Scholar Rock, C4, Vor and more

...member of the board, will become president and CEO. He was president and CEO of Taris...
BioCentury | Dec 21, 2019
Company News

Dec. 20 Company Quick Takes: Genmab partners with CureVac; plus pair of Biogen deals, Ionis, Akcea-Novartis, Paratek and J&J-Taris

...Taris for bladder cancer Johnson & Johnson (NYSE:JNJ) acquired bladder disease company Taris Biomedical LLC. Taris’...
...candidate, TAR-200, is in Phase Ib testing for muscle-invasive bladder cancer and uses the company’s Taris...
...Staff Writers BIIB080, IONIS-MAPTRx, ionis-biib4rx, isis-biib4rx Genmab A/S CureVac N.V. Ionis Pharmaceuticals Inc. Novartis AG Catalyst Biosciences Inc. Paratek Pharmaceuticals Inc. Johnson & Johnson Taris...
BioCentury | Jun 24, 2019
Company News

Management Tracks: Kress to succeed Moroney at MorphoSys; plus Sutro, Entasis and more

...Michael Morin, who will become the immunotherapy company's CSO. Sarma was president and CEO of Taris...
BioCentury | Oct 19, 2018
Clinical News

Taris' TAR-302 reduces daily incontinence episodes by 75% in Phase Ib

...urge incontinence episodes. TAR-302 was well tolerated. TAR-302 comprises a drug-device combination using the company's Taris...
...at day 42. Taris said it plans to rapidly advance the program into late-stage trials. Taris...
...Mass. Product: TAR-302 Business: Genitourinary Molecular target: Muscarinic receptor Description: Drug-device combination using the company's Taris...
BioCentury | Dec 22, 2017
Financial News

Drug delivery company Taris raises $25M series B

...Drug delivery company Taris Biomedical LLC (Lexington, Mass.) raised $25 million in a series B round...
...20, the company said it partnered with BMS to conduct a Phase Ib trial of Taris'...
...in a series A round in 2015. Taris Biomedical LLC, Lexington, Mass. Jaime De Leon gemcitabine-releasing intravesical system nivolumab Opdivo TAR-200 Taris...
BioCentury | Dec 21, 2017
Financial News

Taris raises $25M series B

...Drug delivery company Taris Biomedical LLC (Lexington, Mass.) raised $25 million in a series B round...
...Wednesday, the company said it partnered with BMS to conduct a Phase Ib trial of Taris'...
...invasive bladder cancer. CBO Christopher Searcy said Taris expects data from both trials in mid-2018. Taris...
BioCentury | Jan 6, 2017
Clinical News

TAR-200: Preliminary Ph Ib data

...or "substantial shrinkage" in 8 patients at the time of cystectomy. TAR-200 was well tolerated. Taris...
...intravesical system (TAR-200) (formerly TD-210) Business: Cancer Molecular target: NA Description: Drug-device combination using the Taris...
...analysis of biomarkers Status: Preliminary Phase Ib data Milestone: Start Phase II (2017) Julian Zhu gemcitabine-releasing intravesical system GemRIS TAR-200 Taris...
BioCentury | Aug 15, 2016
Clinical News

GemRIS: Phase Ib started

...NMIBC before transurethral resection of bladder tumors. TAR-200 is in Phase Ib testing for MIBC. Taris...
...TAR-200 ) (formerly TD-210) Business: Cancer Molecular target: NA Description: Drug-device combination using the Taris...
BioCentury | Jul 25, 2016
Clinical News

GemRIS: Phase Ib started

...7 days at days 0 and 21 in up to 20 patients before radical cystectomy. Taris...
...TAR-200 ) (formerly TD-210) Business: Cancer Molecular target: NA Description: Drug-device combination using the Taris...
Items per page:
1 - 10 of 35
BioCentury | Apr 2, 2021
Management Tracks

BeiGene unveils new CFO; plus Precigen, Alphamab, Flagship, Melinta, Immunome and more

...play Immunome Inc. (NASDAQ:IMNM) hired Dennis Giesing as chief development officer. Giesing was CSO at Taris...
BioCentury | Jul 16, 2020
Management Tracks

NextCure CMO Heller to resign; plus Vertex, Turning Point, Scholar Rock, C4, Vor and more

...member of the board, will become president and CEO. He was president and CEO of Taris...
BioCentury | Dec 21, 2019
Company News

Dec. 20 Company Quick Takes: Genmab partners with CureVac; plus pair of Biogen deals, Ionis, Akcea-Novartis, Paratek and J&J-Taris

...Taris for bladder cancer Johnson & Johnson (NYSE:JNJ) acquired bladder disease company Taris Biomedical LLC. Taris’...
...candidate, TAR-200, is in Phase Ib testing for muscle-invasive bladder cancer and uses the company’s Taris...
...Staff Writers BIIB080, IONIS-MAPTRx, ionis-biib4rx, isis-biib4rx Genmab A/S CureVac N.V. Ionis Pharmaceuticals Inc. Novartis AG Catalyst Biosciences Inc. Paratek Pharmaceuticals Inc. Johnson & Johnson Taris...
BioCentury | Jun 24, 2019
Company News

Management Tracks: Kress to succeed Moroney at MorphoSys; plus Sutro, Entasis and more

...Michael Morin, who will become the immunotherapy company's CSO. Sarma was president and CEO of Taris...
BioCentury | Oct 19, 2018
Clinical News

Taris' TAR-302 reduces daily incontinence episodes by 75% in Phase Ib

...urge incontinence episodes. TAR-302 was well tolerated. TAR-302 comprises a drug-device combination using the company's Taris...
...at day 42. Taris said it plans to rapidly advance the program into late-stage trials. Taris...
...Mass. Product: TAR-302 Business: Genitourinary Molecular target: Muscarinic receptor Description: Drug-device combination using the company's Taris...
BioCentury | Dec 22, 2017
Financial News

Drug delivery company Taris raises $25M series B

...Drug delivery company Taris Biomedical LLC (Lexington, Mass.) raised $25 million in a series B round...
...20, the company said it partnered with BMS to conduct a Phase Ib trial of Taris'...
...in a series A round in 2015. Taris Biomedical LLC, Lexington, Mass. Jaime De Leon gemcitabine-releasing intravesical system nivolumab Opdivo TAR-200 Taris...
BioCentury | Dec 21, 2017
Financial News

Taris raises $25M series B

...Drug delivery company Taris Biomedical LLC (Lexington, Mass.) raised $25 million in a series B round...
...Wednesday, the company said it partnered with BMS to conduct a Phase Ib trial of Taris'...
...invasive bladder cancer. CBO Christopher Searcy said Taris expects data from both trials in mid-2018. Taris...
BioCentury | Jan 6, 2017
Clinical News

TAR-200: Preliminary Ph Ib data

...or "substantial shrinkage" in 8 patients at the time of cystectomy. TAR-200 was well tolerated. Taris...
...intravesical system (TAR-200) (formerly TD-210) Business: Cancer Molecular target: NA Description: Drug-device combination using the Taris...
...analysis of biomarkers Status: Preliminary Phase Ib data Milestone: Start Phase II (2017) Julian Zhu gemcitabine-releasing intravesical system GemRIS TAR-200 Taris...
BioCentury | Aug 15, 2016
Clinical News

GemRIS: Phase Ib started

...NMIBC before transurethral resection of bladder tumors. TAR-200 is in Phase Ib testing for MIBC. Taris...
...TAR-200 ) (formerly TD-210) Business: Cancer Molecular target: NA Description: Drug-device combination using the Taris...
BioCentury | Jul 25, 2016
Clinical News

GemRIS: Phase Ib started

...7 days at days 0 and 21 in up to 20 patients before radical cystectomy. Taris...
...TAR-200 ) (formerly TD-210) Business: Cancer Molecular target: NA Description: Drug-device combination using the Taris...
Items per page:
1 - 10 of 35